Pharmaceutical lobbying spend rose 32% in '07

Share this article:
Pharmaceutical industry spending on lobbying rose 32% to $168 million in 2007, according to the Center for Public Integrity.

With the FDA Amendments Act and other contentious legislation affecting the industry in play, PhRMA was the top industry spender, shelling out nearly $23 million on lobbying – a 26% increase in spending over 2006. The trade group and its allies got their money's worth, as restrictions on marketing were scuttled.

Among individual companies, Amgen was the biggest spender, dropping $16.2 million on lobbying amid government investigations centered on its anemia franchise. Next up was Pfizer, at $13.8 million, followed by Roche ($9 million), Sanofi-Aventis ($8.4 million), GlaxoSmithKline ($8.2 million) and Johnson & Johnson ($7.7 million).

Altogether, the industry has spent more than $1 billion on lobbying over the past decade, said the Center for Public Integrity, which based its analysis on Senate Office of Public Records data. The group's report is titled Pushing prescriptions: how the drug industry sells its agenda at your expense.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.